New generation of mesenchymal stem cells-based therapy for acute myocardial infarction: from bench to bedside

Value Added Abstracts

Peisen Huang

Abstract

Despite stem cell therapy has, for past two decades, emerged as one of the most promising therapeutic strategies to repair or regenerate post infarct myocardium, meta-analysis of randomized clinical trials indicated that cell therapy increased left-ventricular ejection fraction (LVEF) by just 3.17% in patients with acute myocardial infarction (AMI). The low recruitment, poor survival and limited engraftment of transplanted mesenchymal stem cells (MSCs) in the ischemic environment are still the main hurdles that limit the therapeutic potential of MSCs. For the past decade, our studies demonstrated that atorvastatin (ATV) treatment improved the survival of MSCs, and ATV pretreated MSCs (ATV-MSCs) exhibited enhanced engraftment to injured myocardium. Our recent studies found that combined treatment with ATV and ATV-MSCs or multiple ATV-MSCs transplantation significantly enhanced the targeted recruitment and survival of transplanted MSCs, and resulted in subsequent cardiac function improvement by augmenting SDF-1/CXCR4 signaling. Exosomes obtained from ATV-MSCs also have significantly enhanced therapeutic efficacy for treatment of AMI through lncRNA H19/miR-675 mediated endothelial cell function regulation passway. We also test the efficacy of such kind of ATV treatment combined stem cells transplantation in patients suffering from anterior ST-elevated myocardial infarction (STEMI) and found significantly increased LVEF change values of 7.6% compared with control group. These strategies of enhancing therapeutic efficacy by ATV treatment represent the new generation of MSC-base therapy, which can achieve enhanced recruitment and survival of transplanted cells and also convenience for clinical application.

Relevant Publications in Journal of Cytology & Histology